アドレナリン作動薬：混合作用薬

Mixed-acting adrenergic agonists both stimulate adrenoceptors directly and indirectly release stored catecholamines from nerve terminals, amplifying the adrenergic response. Direct-acting agents only bind to receptors. Mixed-acting agents like ephedrine and pseudoephedrine lack a catechol moiety, making them resistant to metabolic degradation and extending their duration of action compared to endogenous catecholamines.

Ephedrine and pseudoephedrine lack a catechol moiety, which makes them poor substrates for metabolizing enzymes. This structural difference prevents rapid degradation, increasing their oral bioavailability and allowing them to reach systemic circulation effectively. Their lipophilicity also enhances absorption and CNS penetration, though they remain less potent than endogenous catecholamines.

Ephedrine is used orally as a sympathomimetic agent for treating asthma and managing anesthesia-induced hypotension due to its cardiac stimulation and vasoconstriction effects. However, it is a less potent bronchodilator than isoprenaline or adrenaline. Its central stimulatory effects have led to abuse as a performance enhancer, limiting its therapeutic application.

Pseudoephedrine, an ephedrine isomer with predominantly indirect action, is orally effective with fewer central nervous system effects than ephedrine. These reduced CNS effects make it suitable for nasal decongestant use without significant stimulatory side effects. Its indirect mechanism of action and safety profile favor its use for congestion relief over asthma treatment.

Mixed-acting adrenergic agonists depend on releasing stored neurotransmitters for their indirect effects. Prior treatment with catecholamine-depleting agents like guanethidine or reserpine significantly reduces the agonist response by eliminating available stored catecholamines. This demonstrates the importance of the indirect mechanism in mixed-acting agent efficacy.

Pseudoephedrine is commonly used as a precursor in illegal methamphetamine production. Due to this abuse potential, its sale is strictly regulated to prevent diversion for illicit drug synthesis. Despite its legitimate therapeutic use as a decongestant, regulatory restrictions limit its availability and distribution.

Mixed-acting adrenergic agonists like ephedrine and pseudoephedrine lack a catechol moiety present in endogenous catecholamines. This absence makes them poor substrates for metabolizing enzymes, preventing rapid degradation and increasing their duration of action. This structural modification is key to their extended therapeutic effect compared to natural catecholamines.